{
    "organizations": [],
    "uuid": "c054f53e48221583367d61725d18e20fcd740d22",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hubei-biocause-pharmaceuticals-pre/brief-hubei-biocause-pharmaceuticals-preliminary-2017-net-profit-down-sees-q1-net-profit-rising-idUSH9N1RM00Y",
    "ord_in_thread": 0,
    "title": "BRIEF-Hubei Biocause Pharmaceutical's Preliminary 2017 Net Profit Down, Sees Q1 Net Profit Rising",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Hubei Biocause Pharmaceutical Co Ltd :\n* SAYS PRELIM 2017 NET PROFIT DOWN 21.9 PERCENT AT 1.4 BILLION YUAN ($222.79 million)\n* SAYS IT SEES Q1 NET PROFIT TO RISE 172.7-218.2 PCT Y/Y VS 110 MLN YUAN YEAR AGO\n* SAYS INSURANCE UNIT'S Q1 PREMIUM INCOME TOTALLED 27.15 BILLION YUAN Source text in Chinese: bit.ly/2v63iKP ; bit.ly/2qpjEJ7 ; bit.ly/2IIAFFE Further company coverage: ($1 = 6.2840 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)\n ",
    "published": "2018-04-11T17:48:00.000+03:00",
    "crawled": "2018-04-12T13:50:11.038+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hubei",
        "biocause",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "prelim",
        "net",
        "profit",
        "percent",
        "billion",
        "yuan",
        "million",
        "say",
        "see",
        "q1",
        "net",
        "profit",
        "rise",
        "pct",
        "v",
        "mln",
        "yuan",
        "year",
        "ago",
        "say",
        "insurance",
        "unit",
        "q1",
        "premium",
        "income",
        "totalled",
        "billion",
        "yuan",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "chinese",
        "yuan",
        "renminbi",
        "reporting",
        "hong",
        "kong",
        "newsroom"
    ]
}